It is known that some mutated peptides, such as those resulting from missense mutations and frameshift insertions, can bind to the major histocompatibility complex and be presented to antitumor T-cells on the surface of a tumor cell. These peptides are termed neoantigen and it is important to understand this process for cancer immunotherapy. Here, we introduce an R package that can predict a list of potential neoantigens from a variety of mutations, which include not only somatic point mutations but insertions, deletions, and structural variants. Beyond the existing applications, this package is capable of attaching and reflecting several additional information, e.g., wild-type binding capability, allele specific RNA expression levels, single nucleotide polymorphism information, and combinations of mutations to filter out infeasible peptides as neoantigen.
Introduction
Recent technological advances in massively parallel sequencing have enabled 2 identification of genetic variants, e.g., single nucleotide variants (SNVs) and insertions 3 or deletions (Indels), in individual cancer patients. Furthermore, substantial evidence 4 indicates that tumor-specific peptides that result from such variations can bind to a 5 major histocompatibility complex (MHC) molecule and be presented to antitumor 6 T-cells on the surface of a tumor cell. Identification of such tumor-specific peptides, 7 termed neoantigens, has been receiving increasing attention because of its numerous 8 potential applications in cancer immunotherapy.
9
To identify the possible presence of neoantigens in individual tumor, we have to 10 predict whether mutated peptides can bind to the patient's human leukocyte 11 antigens (HLAs). Several computational methods such as netMHCpan [4] have been 12 proposed to predict the binding capability, including binding affinity and percentage 13 1/4 rank of affinity. To apply these methodologies, we need to determine the patient's 14 HLA types and prepare a list of tumor-specific peptides obtained from sequencing 15 data. Designing such peptides requires not only mutation information, but also the 16 reference sequences with their coding protein information because they are fractions of 17 expressed mutated proteins. Even after the prediction of the binding capability of 18 such mutated peptides, further classification filters should be applied to the selection, 19 e.g., a comparison in binding affinity between wild-type and mutated peptides and the 20 evaluation of allele specific RNA expression levels.
21
To automate this process and easily identify tumor-specific neoantigens, some 22 computational tools have been developed [2, 3] . These tools greatly help to obtain 23 predicted results; however, a few tools can employ mutation data (such as variant call 24 format (vcf) files) in a local analytical environment such as the R. In addition, the 25 existing tools are applicable only for the prediction of HLA Class I binding and for 26 handling of SNVs and Indels at best, but not for the prediction of HLA Class II 27 binding and handling of structural variants (SVs). Moreover, they lack detailed 28 considerations, e.g., reflecting SNVs on the frameshift regions and single nucleotide 29 polymorphisms (SNPs) to generated peptides. To address these requirements, we 30 developed an easy and multifunctional R package that can produce a list of candidate of the functions among pVACseq [3] and MuPeXI [2] , and our R package (neoantimon) 49 is displayed in Table 1 . One can install this package from a GitHub repository and use 50 it in the R environment on Mac/Linux. 
